This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Is McKesson (MCK) Up 0.1% Since Last Earnings Report?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MCK or WST: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MCK vs. WST: Which Stock Is the Better Value Option?
Why McKesson (MCK) Could Be a Top Value Stock Pick
by Zacks Equity Research
McKesson (MCK) seems to be a good value pick, as it has decent revenue metrics to back up its earnings, and is seeing solid earnings estimate revisions as well.
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health
by Zacks Equity Research
Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health
4 Finest Value Stocks Based on Discounted PEG
by Urmimala Biswas
A lower PEG ratio, preferably less than 1, indicates both undervaluation and solid future growth potential of a stock.
Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson
McKesson Corporation Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor McKesson Corporation
5 Great GARP Stocks Based on Discounted PEG
by Urmimala Biswas
PEG-based investing can be more rewarding with the addition of a few other relevant parameters.
Bleak Outlook for Medical Dental Supplies Industry
by Sreyoshi Mukherjee
Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.
5 Stocks to Watch as Fatalities Due to Coronavirus Rise
by Zacks Equity Research
Coronavirus is ravaging China and several other countries. With no cure yet, health officials are struggling to stop its spread. Demand for medical supplies like masks is up manifold.
Company News for Feb 5, 2020
by Zacks Equity Research
Companies In The News Are: RCL, RL, SPG, MCK.
McKesson (MCK) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results gain from higher revenues and solid show by U.S. Pharmaceutical and Specialty Solutions, Medical-Surgical Solutions and Other segments.
McKesson (MCK) Tops Q3 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 7.63% and -0.42%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Earnings Season Could Be Great for McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Uber (UBER) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Higher ridesharing revenues are likely to have boosted Uber's (UBER) top line in fourth-quarter 2019.
What's in Store for Cardinal Health's (CAH) Q2 Earnings?
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter earnings are likely to reflect better-than-expected performance at Pharmaceutical and Medical segments.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to have aided Cerner's (CERN) Q4 earnings. However, contraction in gross margin is likely to have been a dampener.
McKesson (MCK) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) core U.S. Pharmaceutical and Specialty Solutions unit is expected to reflect in fiscal Q3 results.
MCK vs. ALGN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
MCK vs. ALGN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: McKesson, Chipotle Mexican Grill, Microchip Technology, Kellogg and CDW
by Zacks Equity Research
The Zacks Analyst Blog Highlights: McKesson, Chipotle Mexican Grill, Microchip Technology, Kellogg and CDW
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
6 Top Large-Cap Stocks Set to Soar on Earnings Next Week
by Nalak Das
In line with improving earnings results, six large-cap stocks are poised to beat earnings estimates next week.
The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, salesforce.com, L3Harris, McKesson and Synopsys
Is McKesson (MCK) a Profitable Stock for Value Investors?
by Zacks Equity Research
McKesson (MCK) is a good value-oriented pick for investors from all angles.